Australia markets open in 2 hours 49 minutes

iBio, Inc. (IBIO)

NYSE American - NYSE American Delayed price. Currency in USD
Add to watchlist
2.3300+0.1800 (+8.37%)
At close: 04:00PM EDT
2.3900 +0.06 (+2.58%)
After hours: 04:45PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.1500
Open2.1700
Bid2.2800 x 1400
Ask2.4500 x 36900
Day's range2.0501 - 2.4700
52-week range1.0200 - 19.0000
Volume593,365
Avg. volume3,930,262
Market cap20.093M
Beta (5Y monthly)-3.25
PE ratio (TTM)N/A
EPS (TTM)-15.2500
Earnings date14 May 2024 - 18 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

    Strengthened cash position with investment by healthcare specialist investorsExpanding into cardio-metabolic space through AstralBio collaboration BRYAN, Texas and SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today reported financial results for the third quarter ended March 31, 2024 and provided a corporate update. “In our third fiscal quarter, we continued to advance toward our goal

  • GlobeNewswire

    iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

    – Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments – – iBio to use its patented generative AI/Machine Learning platform to discover, engineer and develop obesity-focused therapeutic targets – – Concurrent $15M PIPE financing, announced yesterday, extends cash runway through fiscal year 2025 and provides support for collaboration – – Company to host webcasted conference call today at 8:30 a.m. EDT to discuss AstralBio collaboration – B

  • GlobeNewswire

    iBio Announces $15.0 Million Private Placement

    – Purchase price of $2.85 represents a premium of 148+% to last close – BRYAN, Texas and SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announces today that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds to the Company of approximately $15.0 million, before deducting placement